Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFLUENCE: Nivolumab, Ipilimumab, SBRT, and Influenza Vaccine in Pancreatic Cancer
NCT05116917Phase 2Terminated
- Sponsor
- Herlev Hospital
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza vaccine in pancreatic cancer (PC), sponsored by Herlev Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Nov 2021; status: terminated.
02
Drugs
influenza vaccine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05116917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116917.